2026-04-29T06:15:51Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/233172024-11-29T02:04:58Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud author Martinez-Font, Esther author Pérez-Capó, Marina author Vogler, Oliver author Martin-Broto, Javier author Alemany, Regina author Obrador-Hevia, Antonia 2024-09-18T06:44:08Z 2024-09-18T06:44:08Z 2021-11 Martinez-Font E, Perez-Capo M, Vogler O, Martin-Broto J, Alemany R, Obrador-Hevia A. WNT/beta-Catenin Pathway in Soft Tissue Sarcomas: New Therapeutic Opportunities? Cancers. 2021 Nov;13(21):5521. https://hdl.handle.net/20.500.13003/19913 https://hdl.handle.net/20.500.12105/23317 34771683 10.3390/cancers13215521 2072-6694 Cancers 2-s2.0-85118344927 718590600001 L2014410581 Simple Summary. The WNT/beta-catenin signaling pathway is involved in fundamental processes for the proliferation and differentiation of mesenchymal stem cells. However, little is known about its relevance for mesenchymal neoplasms, such us soft tissue sarcomas (STS). Chemotherapy based on doxorubicin (DXR) still remains the standard first-line treatment for locally advanced unresectable or metastatic STS, although overall survival could not be improved by combination with other chemotherapeutics. In this sense, the development of new therapeutic approaches continues to be an unmatched goal. This review covers the most important molecular alterations of the WNT signaling pathway in STS, broadening the current knowledge about STS as well as identifying novel drug targets. Furthermore, the current therapeutic options and drug candidates to modulate WNT signaling, which are usually classified by their interaction site upstream or downstream of beta-catenin, and their presumable clinical impact on STS are discussed. Soft tissue sarcomas (STS) are a very heterogeneous group of rare tumors, comprising more than 50 different histological subtypes that originate from mesenchymal tissue. Despite their heterogeneity, chemotherapy based on doxorubicin (DXR) has been in use for forty years now and remains the standard first-line treatment for locally advanced unresectable or metastatic STS, although overall survival could not be improved by combination with other chemotherapeutics. In this sense, the development of new therapeutic approaches continues to be a largely unmatched goal. The WNT/beta-catenin signaling pathway is involved in various fundamental processes for embryogenic development, including the proliferation and differentiation of mesenchymal stem cells. Although the role of this pathway has been widely researched in neoplasms of epithelial origin, little is known about its relevance for mesenchymal neoplasms. This review covers the most important molecular alterations of the WNT signaling pathway in STS. The detection of these alterations and the understanding of their functional consequences for those pathways controlling sarcomagenesis development and progression are crucial to broaden the current knowledge about STS as well as to identify novel drug targets. In this regard, the current therapeutic options and drug candidates to modulate WNT signaling, which are usually classified by their interaction site upstream or downstream of beta-catenin, and their presumable clinical impact on STS are also discussed. eng Soft tissue sarcoma WNT signaling Beta-catenin WNT/beta-Catenin Pathway in Soft Tissue Sarcomas: New Therapeutic Opportunities? review article